---
title: "CMC Esophageal Cancer Program"
format: 
  revealjs:
    slide-number: c/t
    width: 1600
    height: 900
    logo: "atriumlogo.jpg"
    footer: "[GI Surgical Oncology Talks](https://gisurgonc.github.io/talks/)"
    css: "lci_styles.css"
    theme: [simple, lci.scss]
    echo: false
  #nanotes_pdf: default
  pdf:
    includes:
      in-header: "preamble.tex"
  #pptx: 
    #reference-doc: talks.pptx
editor: visual
bibliography: zotero.bib
---

## Esophageal Cancer Treatment Categories

| Category             |   Stage    | Treatment                  |
|----------------------|:----------:|:---------------------------|
| [Superficial Tumors] |    T1a     | Endoscopic Therapy         |
| [Localized Tumors]   |   T1b T2   | Surgery                    |
| [Locally advanced]   | T3 or N^+^ | Chemo$\pm$ RT → Surgery    |
| [Metastatic]         |     M1     | Chemotherapy +/- Radiation |


## Superficial Tumor Workup

-   Endoscopic Ultrasound
-   Endoscopic Mucosal Resection
    -   Diagnostic (T staging)
    -   May be therapeutic for T1a tumors

## Endoscopic Musocal Resection

:::: {.columns align="center"}
::: {.column width="50%"}
![T1 Tumor](images/t1a_nolabel){fig-align="center"}
:::

::: {.column width="50%"}


![Saline Lift](images/t1a_lift2.png){fig-align="center"}
:::
::::


## Endoscopic Musocal Resection

:::: {.columns align="center"}
::: {.column width="50%"}
![Snare Excision](images/tumor_EMR_snare.png){fig-align="center"}
:::

::: {.column width="50%"}
![](images/t1a_postemr.png){fig-align="center"}
:::
::::



## EMR Favorable Features

:::: {.columns align="center"}
::: {.column width="50%"}
- Clear Margins
- Size <2cm
- No Lymphovascular/Perineural Invasion
- Well-differentiated


- Overall good prognosis
- EGD in 6 months for surveillance
:::

::: {.column width="50%"}
![](images/emr_favorable_zoom.png){fig-align="center"}
:::
::::


## EMR Unfavorable Features

:::: {.columns align="center"}
::: {.column width="50%"}
- Involved Margins
- Size >2cm
- Lymphovascular/Perineural Invasion
- Poorly differentiated


- High risk for recurrence
- EGD in 3 months for surveillance
:::

::: {.column width="50%"}
![](images/EMR_unfavorable_zoom.png){fig-align="center"}
:::
::::

## EMR Deep Positive Margin


:::: {.columns align="center"}
::: {.column width="50%"}
Positive deep margin on EMR: likely understaged.

High risk of lymph node metastasis

Recommendation for Surgery
:::

::: {.column width="50%"}
![](images/EMR_Positive_Deep.png){fig-align="center"}
:::
::::


## Localized Esophageal Tumors

Patients staged as uT2 N0 are candidates for primary surgery. *However:*

-   EUS has a 25% rate of understaging uT2 N0 tumors
-   Understaged patients treated with surgery need chemo or chemoRT postop

## Asymptomatic Esophageal Tumors (minimal dysphagia)

-   EUS to distinguish T2 from T3 tumors
  -   uT2 N0 $\rightarrow$ CT chest/abdomen/pelvis $\rightarrow$ Esophagectomy
  -   uT3 or N1 $\rightarrow$ PET $\rightarrow$ neoadjuvant therapy

Patients with dysphagia almost always are T3 tumors (and don't need EUS)

## Symptomatic Esophageal Tumors (dysphagia)

Patients with: 

- Dysphagia to solids
- Weight loss
- Tumor length \>3cm are unlikely to have T1-2 tumors 

$\Rightarrow$ Initial evaluation with PET

## EUS in Patients with Dysphagia

Memorial Sloan Kettering patients with esophageal cancer:

-   61 with dysphagia, 54 (89%) were found on EUS to have uT3-4 tumors.
-   53 without dysphagia, 25 (47%) were uT1-2 $\rightarrow$ candidates for primary surgery.

EUS can be omitted for patients with dysphagia, but is useful in those *without* dysphagia.

::: aside
[@ripley226]
:::

## Squamous Cell Carcinoma



:::: {.columns align="center"}
::: {.column width="50%"}
Standard Treatment: ChemoRT (CROSS Regimen)

- Weekly Carboplatin + Paclitaxel
- 5040 cGy radiation in 28 fractions


CROSS trial had 49% pCR for squamous cell carcinoma

$\Rightarrow$ Majority of patients never need surgery
:::

::: {.column width="50%"}
![Surgery vs ChemoRT$\rightarrow$ Surgery by Histology](images/shapiro_1090_fig2b.png){fig-align="center"}
:::
::::


## Restaging after ChemoRT - SCCa

![Restaging after ChemoRT](images/CRT_surgical_candidate.jpg){fig-align="left"}

## Immediate Surgery Strategy

![ChemoRT  $\rightarrow$  Immediate Surgery](images/CRT_immediate_surgery.jpg){fig-align="left"}

Difficult to justify immediate surgery for squamous cell with 50% pCR rate


## Restaging after ChemoRT - SCCa

![Restaging after ChemoRT](images/CRT_restaging_EGD.jpg){fig-align="left"}

## Restaging after ChemoRT - SCCa

![ChemoRT $\rightarrow$ EGD Positive](images/CRT_restaging_EGD_pos.jpg){fig-align="left"}

## Restaging after ChemoRT - SCCa

![ChemoRT $\rightarrow$ EGD Negative](images/CRT_restaging_EGD_neg.jpg){fig-align="left"}

## Active Surveillance for SCCa Esophagus

![ChemoRT $\rightarrow$ EGD Negative](images/CRT_AS_outcome_SCCA.jpg){fig-align="left"}




## SANO Surveillance Schema

![SANO Clinical Trial Schema](images/SANO_schema_notext.jpg){fig-align="left"}

::: aside
[@vanderwilkS1470]
:::


## SANO Surveillance Schema

![SANO Clinical Trial Schema](images/SANO_schema_text.jpg){fig-align="left"}

::: aside
[@vanderwilkS1470]
:::


## Adenocarcinoma

CROSS data would suggest benefit from preoperative ChemoRT is less dramatic with adenocarcinoma





:::: {.columns align="center"}
::: {.column width="50%"}
CROSS data: benefit from preoperative ChemoRT is less dramatic with adenocarcinoma
:::

::: {.column width="50%"}
![Surgery vs ChemoRT$\rightarrow$ Surgery by Histology](images/shapiro_1090_fig2b.png){fig-align="center"}
:::
::::


## CROSS Treatment Failures


![Primary benefit of chemoRT is reducing locoregional and mixed failuressi](images/eyck_modified.png){fig-align="left"}

::: aside
[@shapiro1090]
:::




## ESOPEC: Periop Chemo (FLOT) vs ChemoRT (CROSS)


![ChemoRT $\rightarrow$ EGD](images/ESOPEC_survival_modified.png){fig-align="left"}

::: aside
[@hoeppner323]
:::

## Locally Advanced Adenocarcinoma

::::: columns
::: {.column width="50%"}
**Chemo + Radiation**

-   Better tolerated
-   Port usually placed
-   More dysphagia (last 2 weeks of Tx)
-   Dysphagia resolves 2-3 weeks later
-   More likely to need feeding tube
:::

::: {.column width="50%"}
**Chemotherapy**

-   More effective
-   More toxicity (neutropenia)
-   Port always required
-   Eating slowly improves
-   Less likely to need feeding tube
:::
:::::



## Active Surveillance for Adenocarcinoma after ChemoRT

![ChemoRT $\rightarrow$ EGD Negative](images/CRT_AS_outcome_ACA.jpg){fig-align="left"}




## Esophagectomy at Carolinas Medical Center

- Minimally-invasive approach
- 500+ cases since 2007 (JCS)
- Laparoscopic/VATS $\rightarrow$ Robotic
- Anastomotic leak 8%
- 90-day mortality 5.5%

## Frailty Assessment

![Grip Strength $\rightarrow$ CT Body Composition for evaluation of frailty](images/CMC_slides/HGS_CT.png){fig-align="left"}

::: aside
[@colcord3040]
:::


## Body Composition and Age Predict Operative Mortality

![90-day mortality after esophagectomy=$f$(age + body composition)](images/CMC_slides/BC_90Day_XY.png){fig-align="left"}

::: aside
[@sanderfera]
:::

## Body Composition and Age Predict Operative Mortality

![90-day mortality esophagectomy =$f$(age + body composition)](images/CMC_slides/BC_90Day_Matrix.png){fig-align="left"}



## Can Body Composition Predict Benefit of Surgery?

316 esophageal cancer treated initially with chemo + radiation​

- Surgery in 254
- No surgery in 62

Cohort stratified by age and body composition

- Low Risk (Lower risk 75%)
- High Risk (Higher risk 25%)

## Survival Benefit of Surgery - Normal Muscle

![90-day mortality =$f(age + body composition)$](images/CMC_slides/LowRisk_label.png){fig-align="left"}

::: aside
[@sanderferb]
:::


## Survival Benefit of Surgery - Low Muscle

![90-day mortality =$f(age + body composition)$](images/CMC_slides/HighRisk_label.png){fig-align="left"}


::: aside
[@sanderferb]
:::


##  {background-color="#b2b2b2"}

## Locally Advanced

Treatment depends upon histology:

[Squamous Cell Carcinoma]

[Adenocarcinoma]



## Metastatic

FOLFOX is first-line systemic therapy for metastatic GI cancers

-   Dose-limiting toxicity is frequently peripheral neuropathy


## References
